Synthetic peptides related to laminin pentapeptide (YIGSR) fragment. 1996

K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
Department of Studies in Chemistry, Bangalore University, Central College, India.

The synthetic laminin pentapeptide amide fragment (LF), Tyr-Ile-Gly-Ser-Arg-NH2 corresponding to a part of B1 chain of the glycoprotein, laminin, and six of its analogues having structural modifications at positions 1, 3 and 4 were synthesized by solid phase method employing mainly 9-fluorenylmethoxycarbonyl-amino acid trichlorophenyl esters as coupling agents and Merrifield resin as the solid support. Their biological activities were studied in vivo by lung tumor colonization assay and in vitro by cell adhesion assay. The activity of synthetic LF was found to correlate with the earlier reported results in both in vivo and in vitro assays. Among the analogues made, [Tyr4] LF and [Thr4]LF were found to inhibit the lung tumor colonies more efficiently than LF itself in the in vivo assay whereas [D- Ser4]LF exhibited almost the same inhibition as LF.

UI MeSH Term Description Entries
D007797 Laminin Large, noncollagenous glycoprotein with antigenic properties. It is localized in the basement membrane lamina lucida and functions to bind epithelial cells to the basement membrane. Evidence suggests that the protein plays a role in tumor invasion. Merosin,Glycoprotein GP-2,Laminin M,Laminin M Chain,Chain, Laminin M,Glycoprotein GP 2,M Chain, Laminin
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
November 1987, Science (New York, N.Y.),
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
June 1994, Laboratory investigation; a journal of technical methods and pathology,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
December 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
August 2002, The Journal of organic chemistry,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
January 2002, Postepy higieny i medycyny doswiadczalnej,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
January 1995, Bioconjugate chemistry,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
January 2005, American journal of physiology. Cell physiology,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
May 2004, Journal of peptide science : an official publication of the European Peptide Society,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
March 1999, Journal of materials science. Materials in medicine,
K M Sivanandaiah, and V V Babu, and S C Shankaramma, and M Lakshmana, and R Babu, and M A Arif, and M Kumar
February 1998, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!